Roivant Sciences (ROIV) Aktievy
Roivant Sciences Ltd. är ett biofarmaceutiskt företag i klinisk fas som fokuserar på upptäckt, utveckling och kommersialisering av läkemedel och teknologier. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 0/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för ROIV från våra riskkontroller.
ROIV Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$10
FV
268.6% övervärderad intrinsisk rabatt61
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Roivant Sciences Ltd. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$36.86 |
| 52 veckors högsta | US$37.97 |
| 52 veckors lägsta | US$11.54 |
| Beta | 1.13 |
| 1 månads förändring | 5.43% |
| 3 månaders förändring | 23.03% |
| 1 års förändring | 212.11% |
| 3 års förändring | 231.77% |
| 5 års förändring | 271.20% |
| Förändring sedan börsintroduktionen | 254.42% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Aug 17
ROIV: 2026 Autoimmune And Cardiopulmonary Readouts Will Drive Bullish Repricing
Roivant Sciences has its analyst fair value estimate updated from $39.04 to $41.82 as analysts lift price targets toward the mid to high $40s, citing refreshed models after recent earnings, Q1 updates, and a pipeline that is viewed as having multiple upcoming catalysts. Analyst Commentary Recent Street research on Roivant Sciences has clustered around higher fair value targets and updated models after Q1 and prior fiscal Q4 results.Seeking Alpha • Aug 08
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon
Summary Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma, supported by a strong cash position and imminent product launches. ROIV's $4.7 billion pro forma liquidity eliminates near-term dilution risk, enabling commercialization of brepocitinib and continued pipeline investment without adverse equity market reliance. Brepocitinib's FDA Priority Review for dermatomyositis, with potential approval by September 2026, anchors near-term upside, while label expansions target a >280,000 patient opportunity. ROIV's valuation premium reflects pipeline optionality and self-financing strength, but investors must monitor regulatory, capital allocation, and minority interest risks. Read the full article on Seeking AlphaRecent updates
Uppdatering av berättelse • Aug 17
ROIV: 2026 Autoimmune And Cardiopulmonary Readouts Will Drive Bullish Repricing
Roivant Sciences has its analyst fair value estimate updated from $39.04 to $41.82 as analysts lift price targets toward the mid to high $40s, citing refreshed models after recent earnings, Q1 updates, and a pipeline that is viewed as having multiple upcoming catalysts. Analyst Commentary Recent Street research on Roivant Sciences has clustered around higher fair value targets and updated models after Q1 and prior fiscal Q4 results.Seeking Alpha • Aug 08
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon
Summary Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma, supported by a strong cash position and imminent product launches. ROIV's $4.7 billion pro forma liquidity eliminates near-term dilution risk, enabling commercialization of brepocitinib and continued pipeline investment without adverse equity market reliance. Brepocitinib's FDA Priority Review for dermatomyositis, with potential approval by September 2026, anchors near-term upside, while label expansions target a >280,000 patient opportunity. ROIV's valuation premium reflects pipeline optionality and self-financing strength, but investors must monitor regulatory, capital allocation, and minority interest risks. Read the full article on Seeking Alpha
Uppdatering av berättelse • Aug 03
ROIV: Late Stage Data Catalysts Will Drive Future Upside Potential
Roivant Sciences' updated analyst price target has shifted to $42, with analysts citing refreshed models after recent earnings, pipeline updates, and IMVT-1402 trial data as key drivers behind the change from the prior $45 view. Analyst Commentary Recent Street research on Roivant Sciences has leaned constructive, with several bullish analysts revising their models after earnings, pipeline updates, and new IMVT-1402 data.
Uppdatering av berättelse • Jul 20
ROIV: Future Drug Launches And Legal Settlement Shape Balanced Risk Profile
Roivant Sciences' analyst price target has moved from $21.00 to $31.50, with analysts pointing to refreshed models after recent earnings, updated pipeline views, and new clinical data as key drivers of their revised assumptions. Analyst Commentary Recent research updates on Roivant Sciences show that many firms are lifting their price targets following earnings and new clinical data, but the tone is not uniformly bullish.
Ny berättelse • Jul 19
overprices legal wins and pipeline, ignoring fierce anti-FcRn competition, cash redeployment drag, and holding discounts.
The "Roivant Compounding Fantasy" relies on a lazy sum-of-the-parts calculation, treating binary litigation windfalls and a crowded autoimmune pipeline as a bulletproof thesis. Here is why the market is mispricing the structural friction inside Roivant's hub-and-spoke model: 1.Uppdatering av berättelse • Jul 06
ROIV: Late Stage Pipeline Progress Will Shape Future Upside Potential
Roivant Sciences' analyst fair value estimate has increased from $32.31 to $45.00 as analysts update their models following recent earnings, pipeline data, and revised assumptions on revenue growth, margins, and future P/E levels. Analyst Commentary Recent Street research on Roivant Sciences points to a cluster of higher fair value views, with several bullish analysts revisiting their models after earnings updates and new clinical data.Uppdatering av berättelse • Jun 22
ROIV: 2026 Autoimmune Readouts And Regulatory Milestones Will Drive Repricing
Analysts have raised their average price target on Roivant Sciences to $39.04, citing updated models following recent earnings, pipeline data, and revised assumptions regarding the discount rate, profit margin, and forward P/E. Analyst Commentary Recent research updates on Roivant Sciences point to a more constructive stance from several firms, with higher price targets tied to refreshed models following quarterly results, pipeline data and changes to key assumptions such as discount rates, profit margins and forward P/E multiples.Analysartikel • Jun 19
Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress
Roivant Sciences (ROIV) has drawn fresh attention after announcing a US$2.25b global settlement with Moderna that ends ongoing patent litigation, along with positive IMVT-1402 rheumatoid arthritis data and Breakthrough Therapy Designation for brepocitinib. See our latest analysis for Roivant Sciences. At a share price of US$31.43, Roivant Sciences has seen a 4.63% 7 day share price return and a 13.47% 90 day share price return. Its 1 year total shareholder return of 174.50% and 3 year total...Uppdatering av berättelse • Jun 06
ROIV: 2026 Autoimmune Readouts And Breakthrough Status Will Drive Repricing
Roivant Sciences' updated analyst price target, which rises from $35.71 to $39.04, reflects analysts' refreshed models following recent earnings, pipeline updates, and data from IMVT-1402 that they view as supportive of the stock's risk and reward profile. Analyst Commentary Street research on Roivant Sciences has recently leaned constructive, with several major firms updating models and adjusting valuation targets after the latest earnings reports and IMVT-1402 data.Uppdatering av berättelse • May 19
ROIV: Settlement Windfall Will Shift Focus Toward 2026 Clinical Readouts
Analysts have increased their average price target on Roivant Sciences by about $0.04 to $35.71, citing updated models that factor in litigation settlement proceeds, the brepocitinib priority review and a lower assumed discount rate, along with adjusted profit margin and future P/E assumptions. Analyst Commentary Recent research updates on Roivant Sciences show a mix of optimism around litigation proceeds and key pipeline milestones, alongside some caution around how much of this is already reflected in current valuations.Uppdatering av berättelse • Apr 21
ROIV: Settlement Cash Will Shift Focus Toward 2026 Late Stage Readouts
The updated analyst price target for Roivant Sciences moves from $33.25 to about $35.67, with analysts pointing to revised models that incorporate the Moderna settlement proceeds, a slightly higher assumed discount rate, modest tweaks to long term profit margin expectations, and a higher future P/E multiple. Analyst Commentary Recent research updates focus heavily on the impact of the Moderna settlement, how the proceeds flow through Roivant Sciences' financial model, and what that might mean for valuation versus execution risk.Uppdatering av berättelse • Apr 05
ROIV: Settlement Cash Will Refocus Story On 2026 Clinical Readouts
Analysts have nudged their average price target for Roivant Sciences to $33, reflecting updated models that factor in the $2.25b litigation settlement with Moderna and the removal of what several firms describe as a major overhang on the story. Analyst Commentary Street research on Roivant Sciences has clustered around two core themes: the impact of the US$2.25b litigation settlement and what that means for valuation, and the shift in focus toward the company’s clinical and execution milestones.Uppdatering av berättelse • Mar 22
ROIV: Moderna Settlement Cash Sets Up 2026 Clinical Readout Repricing
Narrative Update on Roivant Sciences The analyst price target for Roivant Sciences has been adjusted from $32.27 to $33.25. Analysts cite the Moderna litigation settlement, related $2.25b proceeds, and the removal of a major overhang as key supports for their updated models.Uppdatering av berättelse • Mar 07
ROIV: Moderna Settlement Clears Path For 2026 Clinical Readout Upside
Analysts have nudged their average price target for Roivant Sciences higher to about $32, supported by updated models that factor in the $2.25b Moderna settlement. They view the resolution of the litigation as lifting a major overhang and refocusing attention on upcoming clinical readouts.Uppdatering av berättelse • Feb 21
ROIV: 2026 Clinical Readouts Are Expected To Unlock Further Upside
Roivant Sciences' analyst price target has increased from $27.00 to about $31.73 as analysts factor in updated assumptions around revenue growth, margin potential and a lower future P/E based on recent Street research. Analyst Commentary Recent Street research shows a cluster of price target increases for Roivant Sciences, with several firms revisiting their models around revenue potential, profitability and valuation multiples.Uppdatering av berättelse • Feb 06
ROIV: 2026 Trial Results And IP Litigation Are Expected To Unlock Upside
Narrative Update Analysts have lifted their blended price target on Roivant Sciences by US$3, citing recent Street research that points to ongoing batoclimab Phase 3 trial progress, a clearer 2026 data timeline, and Roivant's position in the royalty dispute backdrop with Moderna. Analyst Commentary Street research on Roivant Sciences is generally constructive, with recent notes focusing on valuation support from batoclimab, the timing of key Phase 3 readouts, and the ongoing royalty dispute backdrop with Moderna.Uppdatering av berättelse • Jan 22
ROIV: 2026 Trial Readouts And IP Litigation Are Expected To Drive Upside
Narrative Update: Roivant Sciences (ROIV) Analysts have modestly raised their average price target on Roivant Sciences to about $27, citing updated assumptions around batoclimab trial timelines into 2026 and Roivant's role in ongoing Moderna IP litigation as key factors behind the revised outlook. Analyst Commentary Recent research points to a mixed but generally constructive view on Roivant Sciences, with attention on batoclimab timing and the evolving relationship with Moderna as key inputs into valuation and execution risk.Uppdatering av berättelse • Jan 08
ROIV: 2026 Clinical Readouts And LNP Litigation Are Expected To Drive Upside
Analysts have lifted their price expectations for Roivant Sciences, with the blended fair value estimate moving from US$25.64 to about US$27.00 as they weigh updated Phase 3 timelines, a slightly lower discount rate, and higher assumed future P/E multiples, alongside perceived improvements in counter-party credit quality related to ongoing IP litigation. Analyst Commentary Recent Street research on Roivant Sciences reflects a mix of optimism around the pipeline and valuation support, alongside some caution on execution timing and external legal factors.Uppdatering av berättelse • Dec 15
ROIV: Late Stage Pipeline And LNP Litigation Will Drive Upside Into 2026
Analysts have nudged their blended fair value estimate for Roivant Sciences higher, lifting the implied price target by about $1 to approximately $25.64. They are factoring in a richer future earnings multiple and growing confidence in the company’s late stage pipeline and ongoing litigation optionality, despite slightly softer margin and growth assumptions.Uppdatering av berättelse • Nov 30
ROIV: Positive Phase 3 Data Will Drive Shares Into 2026 And Beyond
The analyst price target for Roivant Sciences has increased from approximately $23.27 to $24.55. Analysts cite stronger revenue growth forecasts and recent positive clinical trial updates as factors driving an improved company outlook.Uppdatering av berättelse • Nov 16
ROIV: Upcoming Data From Phase 3 Trials Will Drive Shares Higher
Analysts have raised their fair value estimate for Roivant Sciences from $20.86 to $23.27 per share. They cite strong Phase 3 trial results, continued clinical progress, and anticipated upcoming catalysts as key factors behind the updated price target.Uppdatering av berättelse • Oct 31
ROIV: Positive Phase 3 Results And Legal Uncertainty Will Shape Medium-Term Outlook
The analyst price target for Roivant Sciences has been increased by approximately $0.82 to $20.86 per share. Analysts cite strong Phase 3 trial results and a positive outlook for brepocitinib as key drivers of their upward revisions.Uppdatering av berättelse • Oct 17
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Analysts have recently increased their price targets for Roivant Sciences. The consensus has moved higher by several dollars per share as positive Phase 3 results for brepocitinib and progress in litigation bolster confidence in the company's outlook.Uppdatering av berättelse • Oct 03
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
The analyst consensus price target for Roivant Sciences has increased from $18.30 to $20.05. Analysts cite strong Phase 3 dermatomyositis data and anticipated commercial potential as key drivers for the upward revision.Uppdatering av berättelse • Sep 18
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Analysts have raised Roivant Sciences’ price target from $17.00 to $18.30, citing bullish expectations for favorable Phase 3 brepocitinib data in dermatomyositis as a key catalyst and reflecting increased optimism around near-term pipeline milestones. Analyst Commentary Bullish analysts expect favorable risk/reward ahead of brepocitinib Phase 3 data in dermatomyositis, with key results anticipated in September.Seeking Alpha • Apr 23
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Summary Roivant Sciences has strengthened its financial position through strategic divestitures, boasting $5.2 billion in cash and assets, enabling robust funding for its late-stage pipeline. The company's FcRn inhibitor platform, led by IMVT-1402, shows promise in autoimmune diseases, with positive clinical readouts validating its potential. Priovant's brepocitinib, targeting TYK2/JAK1 pathways, is advancing in Phase 3 trials for Dermatomyositis and Non-Infectious Uveitis, addressing significant unmet needs. Current market valuations significantly undervalue Roivant's potential peak sales, suggesting substantial upside potential given its strong cash position and de-risked late-stage pipeline. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Summary Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while S&P 500 gained 19% since April. Brepocitinib shows promise for NIU treatment with Phase 2 success, but faces challenges including safety concerns and competition from Humira in the $1.5B market. Mosliciguat, targeting PH-ILD, could compete with Tyvaso ($433.8M in Q3 sales) through once-daily dosing and novel mechanism, pending Phase 2 results. Company maintains strong financials with $5.4B in cash/investments and 6-year runway at current burn rate of $76M monthly. I am downgrading to "hold" given the unclear path to profitability and challenges in differentiating clinical assets, though I still see value in a barbell portfolio. Read the full article on Seeking Alpha
Ny berättelse • Jan 26
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas.Aktieägarnas avkastning
| ROIV | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 1.6% | 6.2% | -0.8% |
| 1Y | 212.1% | 46.3% | 20.5% |
Avkastning vs industri: ROIV översteg US Biotechs branschen som gav 46.3 % under det senaste året.
Avkastning vs Marknaden: ROIV översteg US marknaden som gav 20.5 % under det senaste året.
Prisvolatilitet
| ROIV volatility | |
|---|---|
| ROIV Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: ROIV har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: ROIV s veckovolatilitet ( 5% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2014 | 721 | Matt Gline | roivant.com |
Roivant Sciences Ltd. är ett biofarmaceutiskt företag i klinisk fas som fokuserar på upptäckt, utveckling och kommersialisering av läkemedel och teknologier. Bolagets kliniska produktkandidater omfattar IMVT-1402, en helt human monoklonal antikropp riktad mot FcRn som utvecklas för flera IgG-medierade autoimmuna indikationer; mosliciguat, en inhalerad sGC-aktivator som utvecklas för pulmonell hypertension i samband med interstitiell lungsjukdom; neonatal fragment crystallizable receptor för behandling av indikationerna graves sjukdom, svårbehandlad reumatoid artrit, Sjögrens sjukdom, myastenia gravis, kronisk inflammatorisk demyeliniserande polyneuropati och kutan lupus erythematosus; batoclimab, en helt human monoklonal antikropp för behandling av ögonsjukdomen tyreoidea; och brepocitinib, en potent småmolekylär hämmare av TYK2 och JAK1 som utvecklas för behandling av dermatomyosit, icke-infektiös uveit, kutan sarkoidos och andra immunmedierade sjukdomar. Bolagets ledande program består av mosliciguat, en inhalerad sGC-aktivator för behandling av pulmonell hypertension i samband med interstitiell lungsjukdom och andra kardiopulmonella sjukdomar.
Roivant Sciences Ltd. Sammanfattning av grunderna
| ROIV grundläggande statistik | |
|---|---|
| Börsvärde | US$27.01b |
| Vinst(TTM) | -US$266.25m |
| Intäkter(TTM) | US$7.53m |
3,535x
P/S-förhållande-100.0x
P/E-förhållandeÄr ROIV övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ROIV resultaträkning (TTM) | |
|---|---|
| Intäkter | US$7.53m |
| Kostnad för intäkter | US$731.42m |
| Bruttovinst | -US$723.89m |
| Övriga kostnader | -US$457.64m |
| Intäkter | -US$266.25m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.37 |
| Bruttomarginal | -9,610.89% |
| Nettovinstmarginal | -3,534.96% |
| Skuld/egenkapitalförhållande | 0% |
Hur har ROIV utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/20 22:38 |
| Aktiekurs vid dagens slut | 2026/08/20 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Roivant Sciences Ltd. bevakas av 18 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| William Pickering | Bernstein |
| Jeffrey Walch | Bernstein |
| Chi Meng Fong | BofA Global Research |